|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Herceptin inj[賀癌平 凍晶注射劑] information |
|
|
|
製造商 |
Roche |
|
代理/經銷商 |
Roche |
|
成份 |
Trastuzumab |
|
適應症 |
Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) & radiotherapy (if applicable). |
|
用量 |
Metastatic breast cancer Weekly schedule: Initial loading dose of 4 mg/kg as a 90-min IV infusion. Subsequent dose: 2 mg/kg weekly as a 30-min IV infusion. 3-weekly schedule: Initial loading dose of 8 mg/kg followed by 6 mg/kg 3 weeks later, then 6 mg/kg repeated at 3-weekly intervals, administered as a 90-min infusion. Early breast cancer Initial loading dose of 8 mg/kg followed by 6 mg/kg 3 weeks later, then 6 mg/kg repeated at 3-weekly intervals, administered as a 90-min infusion. Patients w/ early breast cancer should be treated for 1 year or until disease recurrence. |
|
過量 |
View Herceptin[賀癌平] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Pregnancy. |
|
警告 |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Herceptin[賀癌平] detailed prescribing infomation |
|
注意事項 |
eva luate cardiac function prior to and during treatment. Discontinue therapy for cardiomyopathy, anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs. Lactation. |
|
不良反應 |
Cardiomyopathy, infusion reactions, exacerbation of chemotherapy-induced neutropenia, pulmonary toxicity. Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia & myalgia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Herceptin[賀癌平] detailed prescribing infomation]
View more drug interactions with Herceptin[賀癌平] |
|
儲存 |
View Herceptin[賀癌平] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Herceptin[賀癌平] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Herceptin[賀癌平] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Herceptin 凍晶注射劑 |
|
Herceptin 150 mg x 1's |
|
Herceptin 440 mg x 1's |
|
|
|
Manufacturer: |
Roche |
|
Distributor: |
Roche |
|
|
|
|
|
